Harnessing Artificial Intelligence Across The Drug Lifecycle: From Discovery To Optimized Operations
EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES · 26.03.2026
DOI: 10.37521/ejpps31108 ↗Kurz gefasst
Fachartikel in der Zeitschrift EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES, erschienen am 26.03.2026. Verfasst von Kunuku Srinu und 4 weiteren Autor:innen. Die Arbeit nennt 75 Literaturangaben.
Abstract (Originalsprache)
Artificial intelligence (AI) has rapidly emerged as a disruptive force in the pharmaceutical industry, offering transformative applications across the entire drug lifecycle. Traditional drug development is hampered by high costs, extended timelines, and high attrition rates, with only a small fraction of candidate molecules reaching the market. AI-driven approaches provide innovative solutions by harnessing big data, computational modeling, and predictive analytics to accelerate discovery and development while reducing risk. In early-stage discovery, AI facilitates target identification, molecular design, and drug repurposing through deep learning, generative chemistry, and protein structure prediction. Preclinical stages benefit from advanced silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) models, as well as digital pathology tools for toxicity prediction and biomarker discovery. In clinical trials, AI improves patient recruitment, stratification, and monitoring through mining of electronic health records, wearable technologies, and adaptive trial design, while also enabling the creation of synthetic control arms. Regulatory science and pharmacovigilance are enhanced by AI-assisted review of submissions, automated detection of adverse drug reactions, and real-time post-marketing surveillance. Furthermore, AI-powered manufacturing and supply chain solutions enable predictive maintenance, process optimization, and efficient distribution. Despite these advancements, challenges remain, including data quality, model transparency, ethical concerns, and regulatory acceptance. Future integration of multimodal data, federated learning, explainable AI, and digital twins may further accelerate innovation. Overall, AI represents not only a supportive tool but a paradigm shift, holding the potential to make drug development faster, more affordable, and more patient centric.
Zitieren
APA
Srinu, K., Chintapalli, G. S., Mishra, K., Surendra, K., & Kumar, M. V. (2026). Harnessing Artificial Intelligence Across The Drug Lifecycle: From Discovery To Optimized Operations. EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES. https://doi.org/10.37521/ejpps31108
Vancouver
Srinu K, Chintapalli GS, Mishra K, Surendra K, Kumar MV. Harnessing Artificial Intelligence Across The Drug Lifecycle: From Discovery To Optimized Operations. EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES. 2026. doi:10.37521/ejpps31108
BibTeX
@article{Srinu2026,
author = {Srinu, Kunuku and Chintapalli, Gowri Sankar and Mishra, Kirtimaya and Surendra, K and Kumar, M Vinod},
title = {Harnessing Artificial Intelligence Across The Drug Lifecycle: From Discovery To Optimized Operations},
journal = {EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES},
year = {2026},
doi = {10.37521/ejpps31108}
}
EUVIMED